Navigation Links
Hard to Treat Diseases (HTDS) Management Discussion

    Pink Sheets Filings Reply To Shareholders FAQ on Various Past News and
    General Corporate Update

SHENZHEN, China, Oct. 1 /PRNewswire-FirstCall/ - HTDS (HTDS) The issuer's China based operating subsidiary Mellow Hope and Serbia operating Subsidiary Slavica Bio Chem are providing news release to bring attention to today's Pink Sheets filing. The filing found on Pink Sheets HTDS listing or this link

The company hopes that this filing bring its followers and shareholders up to date with various events and pending transactions, and to provide an update on past news releases. The filing is intensive 4 pages covering short sellers, naked short positions. The superficial "skull and bones" icon effecting HTDS, IP rights, cancer project and unsolicited buyer, H1N1 business and pending foreign defamation judgment and other FAQ topics of HTDS followers and shareholders.

The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 1:30pm EST.

To receive regular updates on HTDS please sign up or opt in with your email address at this link

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, please contact; Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, (M&A), (IR)

SOURCE Hard to Treat Diseases

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Pennsylvania Breast Cancer Coalition Offers Seminar on Free Treatment for Breast Cancer
2. New approach for the treatment of malignant brain tumors
3. Treatment of severe burn injuries
4. Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half
5. Ulcerative colitis treatment reduces need for surgery by almost half
6. Cardiac stem cell trial seeks to treat some heart attack patients
7. Study Urges Treatment for Even Mild Gestational Diabetes
8. Chronic pain treatments work better together, says anesthesiologist
9. $16.8 million grant awarded to develop platelet recovery treatments
10. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
11. Researchers develop an integrated treatment for veterans with chronic pain and posttraumatic stress
Post Your Comments:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
Breaking Medicine Technology: